Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment

Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment 1

ATLANTA and MIAMI, March 19, 2020 /PRNewswire/ — Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced a collaboration to rapidly advance DRIVE’s EIDD-2801, a promising oral COVID-19 treatment, into human testing. This collaboration combines Ridgeback’s unique experience advancing drug development efforts in the midst of an on-going disease outbreak with the three decades of experience that the DRIVE executive team has in antiviral drug development and commercialization.

Source: Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment